Spero Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Spero Therapeutics, Inc. (SPRO) reported Revenue from Contract with Customer, Excluding Assessed Tax of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-12
- Spero Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $0.00.
- Spero Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $12.57M, a 24080.77% increase year-over-year.
- Spero Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $12.59M, a 3292.45% increase from fiscal 2024.
- Spero Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $371.00K, a 60.24% decline from fiscal 2023.
- Spero Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $933.00K, a 62.72% decline from fiscal 2022.
- Spero Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $2.50M, a 18.47% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $12.57M derived: sum of 3 quarters · filed 2026-08-12 | $12.57M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | $12.57M derived: sum of 2 quarters · filed 2026-05-13 | $12.57M derived: sum of 3 quarters · filed 2026-05-13 | $12.57M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $12.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $12.57M derived: sum of 2 quarters · filed 2026-03-26 | $12.57M derived: sum of 3 quarters · filed 2026-08-12 | $12.59M 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $12.00K 10-Q · filed 2025-11-13 | $64.00K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | $12.00K 10-Q · filed 2026-08-12 | $64.00K derived: sum of 3 quarters · filed 2026-08-12 | $129.00K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $12.00K 10-Q · filed 2026-05-13 | $64.00K derived: sum of 2 quarters · filed 2026-05-13 | $129.00K derived: sum of 3 quarters · filed 2026-05-13 | $243.00K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $117.00K derived: sum of 2 quarters · filed 2026-03-26 | $231.00K derived: sum of 3 quarters · filed 2026-03-26 | $371.00K 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | $65.00K 10-Q · filed 2025-11-13 | $179.00K derived: sum of 2 quarters · filed 2025-11-13 | $319.00K 10-Q · filed 2025-11-13 | $542.00K derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $114.00K 10-Q · filed 2025-08-12 | $254.00K 10-Q · filed 2025-08-12 | $477.00K derived: sum of 3 quarters · filed 2025-08-12 | $695.00K derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $140.00K 10-Q · filed 2025-05-13 | $363.00K derived: sum of 2 quarters · filed 2025-05-13 | $581.00K derived: sum of 3 quarters · filed 2025-05-13 | $850.00K derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $441.00K derived: sum of 2 quarters · filed 2025-03-27 | $710.00K derived: sum of 3 quarters · filed 2025-03-27 | $933.00K 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $218.00K 10-Q · filed 2024-11-14 | $23.38M 10-Q · filed 2023-11-13 | $487.00K derived: sum of 2 quarters · filed 2024-11-14 | $710.00K 10-Q · filed 2024-11-14 | $24.91M 10-Q · filed 2023-11-13 | $988.00K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $269.00K 10-Q · filed 2024-08-05 | $788.00K 10-Q · filed 2023-08-10 | $492.00K 10-Q · filed 2024-08-05 | $1.53M 10-Q · filed 2023-08-10 | $770.00K derived: sum of 3 quarters · filed 2024-08-05 | $1.85M derived: sum of 4 quarters · filed 2024-08-05 | ||
| 2023-03-31 | $223.00K 10-Q · filed 2024-05-15 | $740.00K 10-Q · filed 2023-05-11 | $501.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.58M derived: sum of 3 quarters · filed 2024-05-15 | $2.48M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $278.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $1.36M derived: sum of 2 quarters · filed 2024-03-13 | $2.26M derived: sum of 3 quarters · filed 2024-03-13 | $2.50M 10-K · filed 2024-03-13 | $48.58M 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $1.08M 10-Q · filed 2023-11-13 | $1.98M derived: sum of 2 quarters · filed 2023-11-13 | $2.23M 10-Q · filed 2023-11-13 | $2.48M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $896.00K 10-Q · filed 2023-08-10 | $1.14M 10-Q · filed 2023-08-10 | $1.40M derived: sum of 3 quarters · filed 2023-08-10 | $2.11M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $247.00K 10-Q · filed 2023-05-11 | $503.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.21M derived: sum of 3 quarters · filed 2023-05-11 | $3.32M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $256.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $964.00K derived: sum of 2 quarters · filed 2023-03-30 | $3.07M derived: sum of 3 quarters · filed 2023-03-30 | $3.07M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $708.00K 10-Q · filed 2022-11-14 | $2.81M derived: sum of 2 quarters · filed 2022-11-14 | $2.81M 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | $2.11M 10-Q · filed 2022-08-10 | $2.11M 10-Q · filed 2022-08-10 | ||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $38.00K derived: sum of 2 quarters · filed 2022-03-31 | $89.00K derived: sum of 3 quarters · filed 2022-03-31 | $258.00K 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $38.00K 10-Q · filed 2021-11-10 | $89.00K derived: sum of 2 quarters · filed 2021-11-10 | $258.00K 10-Q · filed 2021-11-10 | $954.00K derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $51.00K 10-Q · filed 2021-08-05 | $220.00K 10-Q · filed 2021-08-05 | $916.00K derived: sum of 3 quarters · filed 2021-08-05 | $1.09M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $169.00K 10-Q · filed 2021-05-06 | $865.00K derived: sum of 2 quarters · filed 2021-05-06 | $1.04M derived: sum of 3 quarters · filed 2021-05-06 | $1.10M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | $696.00K 10-K · filed 2020-03-16 | $868.00K derived: sum of 2 quarters · filed 2020-11-05 | $935.00K derived: sum of 3 quarters · filed 2020-11-05 | $4.74M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $172.00K 10-Q · filed 2020-11-05 | $239.00K derived: sum of 2 quarters · filed 2020-11-05 | $4.05M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $67.00K 10-Q · filed 2020-08-06 | $3.87M 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | $3.81M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |